key: cord-0795688-1188z9hj
authors: Patelli, Giorgio; Pani, Arianna; Amatu, Alessio; Scaglione, Francesco; Sartore-Bianchi, Andrea
title: Seroconversion after SARS-CoV-2 mRNA booster vaccine in cancer patients
date: 2022-03-15
journal: Eur J Cancer
DOI: 10.1016/j.ejca.2022.02.032
sha: e55144b2adfd196af8eb51c7a2a5ff0d62310222
doc_id: 795688
cord_uid: 1188z9hj

nan

In the SINFONIA-V study published in the December 2021 edition of the European Journal of Cancer, we sowed that a 5.8% fraction of patients with solid tumors undergoing anticancer treatment do not achieve seroconversion after primary (2 doses) SARS-CoV-2 mRNA vaccination with BNT162b2 or mRNA-1273 (10/171 individuals); this was significantly different as compared with 0.2% of controls without cancer (p <0.001) 1,2 . We report here updated data with the analysis of post-booster serological status in these patients (n=10), Interestingly, we found that among 6 evaluable individuals with pre-boosting confirmed seronegativity, 2 (33%) developed anti-spike antibodies after boosting, whereas the remaining showed persistent seronegative status ( In conclusion, even though a variable percentage of patients with solid tumors display immunization after booster despite seronegativity after previous primary vaccine, there is a subpopulation who persistently fails to achieve seroconversion (roughly one third of those who remained seronegative after primary vaccination) 1, 3, 4 . This finding is concerning, as boosters are the leading strategy to enhance immunization. Further investigation is warranted in this population. In particular, pooling data into consortium efforts would allow to better characterize immune responses in patients with cancer, since individual analyses are underpowered to assess patient and treatment subgroups in detail.

This would also support the sharing of knowledge and resources on immunological and computational analyses to better dissect this vulnerable population. 

Impaired seroconversion after SARS-CoV-2 mRNA vaccines in patients with solid tumours receiving anticancer treatment

Antibody response to BNT162b vaccine is almost universal in health care workers. Results from the RENAISSANCE study: REsponse to BNT162b2 COVID-19 vacciNe -short And long term Immune reSponSe evAluatioN in healthCare workErs

Immunogenicity and safety of BNT162b2 mRNA vaccine booster in actively treated patients with cancer

Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer